Bouygues stock price target raised to EUR56 by JPMorgan on M&A potential

JPMorgan has raised its price target on Bouygues SA to EUR56.00 from EUR49.00, maintaining an Overweight rating, based on the view that market concerns regarding recent guidance and French political risks are overdiscounted. The firm highlights underappreciated upside from Equans' growth, margin improvement, and significant M&A opportunities, especially in French telecom consolidation, which it believes are not reflected in the current share price. JPMorgan finds Bouygues' valuation compelling, trading at 10x P/E with a 14% equity free cash flow yield and projected 5% EBITDA growth, alongside a 15% EPS compound annual growth rate.

Analysis

JPMorgan has upgraded its price target on Bouygues SA to EUR56.00 from EUR49.00 while reiterating an Overweight rating, signaling a strong bullish conviction. The bank's thesis posits that the market has excessively penalized the stock for a recent guidance reduction and perceived French political risks. According to JPMorgan's analysis, significant upside remains underappreciated, particularly from growth and margin enhancement within the Equans business. Furthermore, the firm identifies potential M&A activity as a key catalyst, arguing that opportunities for French telecom industry consolidation are "misunderstood" and not factored into the current share price. The valuation is presented as compelling, with the stock trading at a 10x price-to-earnings ratio and offering a 14% equity free cash flow yield, supported by projections of 5% EBITDA growth and a 15% compound annual growth rate for earnings per share.

Key Decisions for Investors

• Investors may view the current valuation as an attractive entry point, given the stock's 10x P/E ratio, 14% equity free cash flow yield, and a projected 15% EPS compound annual growth rate.
• It is crucial to monitor for any developments related to French telecom industry consolidation or bolt-on acquisitions for the Equans business, as these are identified as key, unpriced catalysts that could unlock further value.
• Investors should weigh JPMorgan's optimistic, contrarian view against the market's existing concerns regarding the company's prior guidance cut and the evolution of French political risks, which were cited as reasons for the stock's recent underperformance.